Clinical Trials Logo

Hepatitis B clinical trials

View clinical trials related to Hepatitis B.

Filter by:

NCT ID: NCT00710216 Withdrawn - Clinical trials for Hepatitis B, Chronic

Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B

EVD
Start date: n/a
Phase: Phase 4
Study type: Interventional

This study examines the effect of telbivudine compared to lamivudine on the early viral kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.

NCT ID: NCT00606099 Withdrawn - Chronic Hepatitis B Clinical Trials

Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B

Start date: November 2007
Phase: Phase 4
Study type: Interventional

This study is designed to evaluate the efficacy and safety of telbivudine 600mg versus adefovir dipivoxil 10mg in patients with compensated chronic hepatitis B.

NCT ID: NCT00409019 Withdrawn - Chronic Hepatitis B Clinical Trials

Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy

Start date: n/a
Phase: Phase 4
Study type: Interventional

The purpose of this study is to find out if taking a combination of telbivudine and adefovir or tenofovir and telbivudine can lower the amount of Hepatitis B virus in patients that have been taking adefovir alone for at least 5 months and have had less than optimal responses. The safety of taking telbivudine and adefovir together or tenofovir and telbivudine together will also be studied.

NCT ID: NCT00051090 Withdrawn - HIV Infections Clinical Trials

Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV

Start date: n/a
Phase: N/A
Study type: Interventional

This study will evaluate the drug telbivudine (LdT) for treatment of hepatitis B virus (HBV) in HIV infected patients. Patients will take telbivudine alone for 24 weeks, add anti-HIV drugs for 24 weeks, then stop taking telbivudine while continuing their anti-HIV drug regimen. To enroll in this study, patients must not be taking any anti-HIV drugs and cannot have taken more than 31 days of treatment with lamivudine (3TC), protease inhibitors (PIs), or nonnucleoside reverse transcriptase inhibitors (NNRTIs).

NCT ID: NCT00051077 Withdrawn - HIV Infections Clinical Trials

Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)

Start date: n/a
Phase: Phase 2
Study type: Interventional

This study will investigate the safety and effectiveness of using adefovir dipivoxil (ADV), pegylated interferon (PEG-INF), and ribavirin (RBV) in patients triple-infected with hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV. Patients in this study must be taking lamivudine (3TC).